HBM Holdings (HKG:2142) said it expects to report a profit of between HK$532 million to about HK$579 million for the six months ended 30 June, according to a Monday Hong Kong bourse filing.
The improvement was mainly driven by proceeds from strategic collaborations, including a global partnership with AstraZeneca that contributed around $175 million from subscription shares, upfront payments, milestones, and option fees.
Interim results are expected by the end of August.
Shares of the company were down about 4% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。